Nirav Shah, MD, MSHP, on Evaluating Zamto-Cel in R/R DLBCL

Commentary
Video

The associate professor of medicine at Medical College of Wisconsin discussed efficacy data presented at the 2025 Tandem Meetings.

This article originally appeared on our sister site, OncLive®.

"Despite some of these poor prognostic indicators, we were happy to report that the overall response rate was [72.8%,] with [50.8%] of patients achieving a complete remission. Many of these remissions were durable."

Zamtocabtagene autoleucel (zamto-cel; MB-CART2019.1), a dual CD19- and CD20-directed noncryopreserved chimeric antigen receptor T-cell (CAR-T) therapy, is currently being evaluated in the phase 2 DALY II USA trial (NCT04792489) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Interim data from this study were recently presented at the 2025 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Honolulu, Hawaii, February 12 to 15, 2025.

During the meeting, CGTLive®'s sister site OncLive®, interviewed Nirav Shah, MD, MSHP, an associate professor of medicine at Medical College of Wisconsin, about the analysis, which included 59 evaluable patients in the modified intention-to-treat population. Shah pointed out that many of these patients had elevated International Prognostic Index (IPI) scores and lactate dehydrogenase (LDH) levels at enrollment, indicating high-risk disease. Although, the overall response rate (ORR) was 72.8%, including a complete remission (CR) rate of 50.8%, despite the adverse prognostic factors. Furthermore, an 11.4 month median duration of response was recorded, and for patients achieving a CR, the median duration of CR was not yet reached as of the data cut-off.

At 6 months, the progression-free survival (PFS) rate was 55%, and the median PFS was 9.0 months. The median overall survival (OS) had not been reached.

Shah explained that continued follow-up will be vital to obtain more mature data. Future analyses will examine the 1- and 2-year outcomes for patients treated during the study.

The safety profile of zamto-cel was favorable, with no cases of grade 3 or higher cytokine release syndrome reported. Immune effector cell–associated neurotoxicity syndrome of grade 3 or higher occurred in 4.3% of patients.

Notably, dual CD19/CD20 targeting was associated with a potential mitigation of antigen loss as a resistance mechanism. Among 27 patients who had disease progression, no antigen loss was observed in 22 patients. CD19 loss and CD20 loss were experienced by 2 patients each, and 1 patient had dual CD19/CD20 loss.

Click here for more coverage of Tandem 2025.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.